An Open-label, Randomized, Parallel Design Trial to Compare the Efficacy of a Sitagliptin-based Metabolic Intervention Versus Standard Diabetes Therapy in Inducing Remission of Type 2 Diabetes
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2016
At a glance
- Drugs Sitagliptin (Primary) ; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REMIT-Sita
- 07 Jun 2017 Biomarkers information updated
- 02 Aug 2016 Status changed from not yet recruiting to recruiting.
- 02 Aug 2016 Planned End Date changed from 1 Apr 2017 to 1 Dec 2018.